Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy

Oncology

Volumn 82, Issue 2, 2012, Pages 108-113

  Suzuki, Akihiro ^a   Xiao, Lianchun ^a   Hayashi, Yuki ^a   Blum, Mariela A ^a   Welsh, James W ^a   Lin, Steven H ^a   Lee, Jeffrey H ^a   Bhutani, Manoop S ^a   Weston, Brian ^a   Maru, Dipen M ^a   Rice, David C ^a   Swisher, Stephen G ^a   Hofstetter, Wayne L ^a   Erasmus, Jeremy ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiotherapy; Esophageal cancer; Gastroesophageal junction cancer; Nomogram; Unresectable cancer

Indexed keywords

AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CORRELATION ANALYSIS; ENDOSCOPIC BIOPSY; ESOPHAGUS CARCINOMA; FEMALE; GASTROESOPHAGEAL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84862810813     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000335951     Document Type: Article

References (14)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146. (Pubitemid 40277094)
3. Brown LM, Devesa SS, Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100: 1184-1187.
4. Brown LM, Swanson CA, Gridley G, et al: Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995; 87: 104-109.
5. Gaast AV, van Hagen P, Hulshof M, Richel D, van Berge Henegouwen MI, Nieuwenhuijzen GA, Plukker JT, Bonenkamp JJ, Steyerberg EW, Tilanus HW, CROSS Study Group: Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study (abstract 4004). J Clin Oncol 2010; 28: 15s.
6. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-1627. (Pubitemid 29211772)
7. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK Jr, Warren G, Washington MK, Willett C, Wright CD, National Comprehensive Cancer Network: Esophageal and Esophagogastric Junction Cancers. J Natl Compr Canc Netw 2011; 9: 830-887.
8. Wu X, Gu J, Wu TT, et al: Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24: 3789-3798. (Pubitemid 46628477)
9. Fukunaga T, Okazumi S, Koide Y, et al: Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39: 1002-1007. (Pubitemid 28270115)
10. Rizk N, Downey RJ, Akhurst T, et al: Preoperative [F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection Ann Thorac Surg 2006 81 1076-1081 (Pubitemid 43247692)
11. Kato H, Nakajima M, Sohda M, et al: The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 2009; 115: 3196-3203.
12. Suzuki A, Xiao L, Hayashi Y, et al: Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011; 117: 4823-4833.
13. Shankar LK, Hoffman JM, Bacharach S, et al: Consensus recommendations for the use of F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47: 1059-1066. (Pubitemid 46939960)
14. Harrell FE Jr, Lee KL, Mark DB: Tutorial in biostatistics. multivariable prognostic model: issues in developing models, evaluating assumption and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.